The launch of a new Biosciences division diversifies Cyprotex’s offering and complements its existing ADME-Tox business. The group has established itself as a speedy, reliable and cost effective pre-clinical Contract Research Organisation (CRO), attributes that we believe are key to customer retention and attraction. The group continues to enhance its service offering, extend its geographical reach and provide cross selling opportunities. We believe Cyprotex has the capability and drive to conti ....
